Serratia marcescens harbouring SME-type class A carbapenemases in Canada and the presence of blaSME on a novel genomic island, SmarGI1-1
Open Access
- 21 March 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (7) , 1825-1829
Abstract
An increasing prevalence since 2010 of Serratia marcescens harbouring the Ambler class A carbapenemase SME prompted us to further characterize these isolates. Isolates harbouring blaSME were identified by PCR and sequencing. Phenotypic analysis for carbapenemase activity was carried out by a modified Hodge test and a modified Carba NP test. Antimicrobial susceptibilities were determined by Etest and Vitek 2. Typing was by PFGE of macrorestriction digests. Whole-genome sequencing of three isolates was carried out to characterize the genomic region harbouring the blaSME-type genes. All S. marcescens harbouring SME-type enzymes could be detected using a modified Carba NP test. Isolates harbouring blaSME were resistant to penicillins and carbapenems, but remained susceptible to third-generation cephalosporins, as well as fluoroquinolones and trimethoprim/sulfamethoxazole. Isolates exhibited diverse genetic backgrounds, though 57% of isolates were found in three clusters. Analysis of whole-genome sequence data from three isolates revealed that the blaSME gene occurred in a novel cryptic prophage genomic island, SmarGI1-1. There has been an increasing occurrence of S. marcescens harbouring blaSME in Canada since 2010. The blaSME gene was found on a genomic island, SmarGI1-1, that can be excised and circularized, which probably contributes to its dissemination amongst S. marcescens.Keywords
This publication has 16 references indexed in Scilit:
- Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP)Journal of Antimicrobial Chemotherapy, 2012
- Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in DetroitDiagnostic Microbiology and Infectious Disease, 2011
- Sensitive Screening Tests for Suspected Class A Carbapenemase Production in Species of EnterobacteriaceaeJournal of Clinical Microbiology, 2009
- Occurrence of an SME-2-producing Serratia marcescens isolate in CanadaInternational Journal of Antimicrobial Agents, 2008
- Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999–2005)Diagnostic Microbiology and Infectious Disease, 2006
- SME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing β-LactamasesAntimicrobial Agents and Chemotherapy, 2006
- Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC ProgrammeDiagnostic Microbiology and Infectious Disease, 2001
- SME-Type Carbapenem-Hydrolyzing Class A β-Lactamases from Geographically Diverse Serratia marcescens StrainsAntimicrobial Agents and Chemotherapy, 2000
- Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6Antimicrobial Agents and Chemotherapy, 1994
- Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolatesAntimicrobial Agents and Chemotherapy, 1990